Seegene, Inc. and Shimadzu Corporation Announces a Strategic Partnership

ROCKVILLE, MD and KYOTO, JAPAN Seegene, Inc. and Shimadzu Corporation today announced a strategic partnership to combine Seegene’s Seeplex(R) multi-pathogen tests with Shimadzu’s MultiNA (1) analytical platform. Under terms of the deal, Shimadzu and Seegene will collaborate on integrating the Seeplex polymerase chain reaction-based tests with Shimadzu’s MultiNA high-speed electrophoresis system to provide a highly sensitive, high-throughput multi-pathogen detection and analysis solution.

“This strategic agreement reinforces our plan to bring solutions, and not only products, to our customers,” said Dr. Jong-Yoon Chun, Founder and Chief Executive Officer, Seegene. “Shimadzu’s MultiNA is outstanding in the market for electrophoresis analysis and a perfect match for the Seeplex family of multi-pathogen tests.”

“Seegene’s novel multi-pathogen detection test working with Shimadzu’s next-generation electrophoresis systems creates an unparalleled screening platform for laboratories around the world,” said Yoshiyuki Togawa, General Manager, Shimadzu. “Seeplex tests running on MultiNA is the fast, accurate and efficient way for laboratories to screen for the most rampant and debilitating pathogens infecting people around worldwide.”

Shimadzu’s MultiNA is a microchip electrophoresis system that quickly and easily performs DNA and RNA nucleic acid size confirmation and quantification. The system uses microchip technology to conduct fully automated high-speed electrophoresis separation, and fluorescence detection to perform high-sensitivity analysis.

Seeplex tests are based on a breakthrough multiplexing PCR technology capable of detecting multiple pathogens in a single tube. Seeplex-based tests deliver maximum specificity, reproducibility and sensitivity and can be applied to a broad range of molecular diagnostics, including human, animal, plant and microorganism. Currently, Seegene’s Seeplex multi-pathogen detection tests offer labs worldwide simple, cost-effective and comprehensive screening for STDs, respiratory viruses, human papillomaviruses, sepsis and pneumonia.

(1) MultiNA is Research Use Only.

About Shimadzu

Founded in 1875, Shimadzu Corporation develops and manufactures analytical and monitoring equipment for science laboratories worldwide. Its products include imaging systems for medical diagnosis such as ultrasound systems and mobile X-ray systems, as well as spectrophotometers and chromatography systems for the life science sector. For more information about Shimadzu’s extensive line of laboratory offerings, please visit www.shimadzu.com.

About Seegene

Seegene, Inc. is pioneering the field of multi-pathogen testing. Seegene applies its novel and proprietary Seeplex system utilizing “DPO (Dual Priming Oligo)” and “ACP (Annealing Control Primer)” to create multi-pathogen tests delivering maximum specificity, reproducibility and sensitivity. With over 360 citations and several patents and patents pending, Seegene has been offering advanced molecular diagnostics services to over 1,200 major global institutes in more than 30 countries. Seegene is actively working with both the scientific and OEM business community. Seegene’s mission is to integrate Seeplex with disease diagnostics to provide a new guideline for effectively treating patients. Seegene was founded in 2000 and is based in Rockville, MD and Seoul, Korea. For more information please visit www.seegene.com.

All trademarks and registered trademarks are property of their respective owners.

Contacts: Sangkil Lee, Ph.D. Seegene Inc. 301-762-9066 Email Contact or Constantine Theodoropulos Boston Communications 617-292-7319 Email Contact

SOURCE: Seegene

< | >